We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today
Read MoreHide Full Article
On Thursday, shares of biotech company GlycoMimetics Inc. (GLYC - Free Report) are skyrocketing, up over 100% to 410.92 per share in afternoon trading after the company announced that the FDA designated one of its drugs as a “Breakthrough Therapy.”
GlycoMimetic’s drug candidate, GMI-1271, treats adult relapsed/refractory acute myeloid leukemia (AML), which is a cancer of the blood and bone marrow; AML is most common type of acute leukemia in adults. The cancer is known for rapid growth of abnormal white blood cells that gather in the bone marrow, preventing normal blood cell production. About 19,900 people are diagnosed every year in the U.S., and roughly 10,400 die from all forms of the disease.
GMI-1271 is an E-selectin antagonist currently in Phase 2 of a Phase 1/2 clinical trial. In the trial, the treatment is being administered in addition to chemotherapy; patients treated with the drug achieved higher than expected remission rates, as well as lower than expected 30- and 60-day mortality rates in early evaluations.
The FDA’s Breakthrough Therapy designation helps companies accelerate the development and review of drug candidates, without changing FDA standards for new drug approval.
“The FDA’s granting to GMI-1271 of Breakthrough Therapy designation will further help GlycoMimetics to accelerate the development of GMI-1271 as a treatment for this very difficult-to-treat patient population," said Helen Thackray, MD, Chief Medical Officer of GlycoMimetics.
“We believe GMI-1271 when combined with chemotherapy has the potential to address an unmet therapeutic need for individuals living with AML. We are encouraged by our clinical results to date, and look forward to working closely with the FDA to bring this novel therapy to patients as quickly as possible,” she continued.
Currently, GLYC is a #3 (Hold) on the Zacks Rank, with a VGM score of ‘F.’
Stocks that Aren't in the News…Yet
You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street.
They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015, with a stellar average gain of +26% per year. See these high-potential stocks now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today
On Thursday, shares of biotech company GlycoMimetics Inc. (GLYC - Free Report) are skyrocketing, up over 100% to 410.92 per share in afternoon trading after the company announced that the FDA designated one of its drugs as a “Breakthrough Therapy.”
GlycoMimetic’s drug candidate, GMI-1271, treats adult relapsed/refractory acute myeloid leukemia (AML), which is a cancer of the blood and bone marrow; AML is most common type of acute leukemia in adults. The cancer is known for rapid growth of abnormal white blood cells that gather in the bone marrow, preventing normal blood cell production. About 19,900 people are diagnosed every year in the U.S., and roughly 10,400 die from all forms of the disease.
GMI-1271 is an E-selectin antagonist currently in Phase 2 of a Phase 1/2 clinical trial. In the trial, the treatment is being administered in addition to chemotherapy; patients treated with the drug achieved higher than expected remission rates, as well as lower than expected 30- and 60-day mortality rates in early evaluations.
The FDA’s Breakthrough Therapy designation helps companies accelerate the development and review of drug candidates, without changing FDA standards for new drug approval.
“The FDA’s granting to GMI-1271 of Breakthrough Therapy designation will further help GlycoMimetics to accelerate the development of GMI-1271 as a treatment for this very difficult-to-treat patient population," said Helen Thackray, MD, Chief Medical Officer of GlycoMimetics.
“We believe GMI-1271 when combined with chemotherapy has the potential to address an unmet therapeutic need for individuals living with AML. We are encouraged by our clinical results to date, and look forward to working closely with the FDA to bring this novel therapy to patients as quickly as possible,” she continued.
Currently, GLYC is a #3 (Hold) on the Zacks Rank, with a VGM score of ‘F.’
Stocks that Aren't in the News…Yet
You are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. Many of these companies are almost unheard of by the general public and just starting to get noticed by Wall Street.
They have been pinpointed by the Zacks system that nearly tripled the market from 1988 through 2015, with a stellar average gain of +26% per year. See these high-potential stocks now>>